Mylan Pharmaceuticals spent the past decade set up the terms of the EpiPen from$57 to $ 600 . Why ? Because they could . The caller did n’t have any substantial challenger . And now one competitor , Teva Pharmaceuticals , a company that has adjudicate and failed to fetch a generic EpiPen to market before , says that their product wo n’t be ready until late 2017 or even 2018 .
Reuters notes that Sigurdur Olafsson , Teva ’s head of global generic medicines , had request a meeting with the FDA evenhandedly recently and the companyhad been drive back . But since the medium firestorm of the past two weeks , “ the FDA has fall back to us and we will have a meeting very , very quickly . ”
Teva ’s previous attempts to make a generic EpiPenhit snagsin examination when the machine was n’t working as intend . The FDA name “ major deficiencies ” in their generic , pass Teva to go back to the drafting card .
Mylan has annunciate that their own generic wine will be available soon , which is a bit funny , since they ’re basically exposing how ridiculous our current system is . When you peel off the EpiPen ™ recording label and replace the precise same product with a Generic Name ™ label , it as if by magic cost half as much .
What ’s one-half of $ 600 retail for a life - make unnecessary drug ? That’dbe $ 300 . All for about $ 1 Charles Frederick Worth of injectable medicine and a different recording label on the bundle .
We have no musical theme what Teva will price their generic EpiPen at , but hopefully it ’ll be something much more reasonable . Even return prices to the 2007 range of $ 57 would be dainty , since they have n’t changed a damn affair about the product . But we ’ll have to wait until tardy 2017 or 2018 to see . Pending FDA approval , of row .
[ Reuters ]
AllergiesMedicine
Daily Newsletter
Get the good tech , science , and acculturation news in your inbox day by day .
News from the future , delivered to your present .
You May Also Like
